Repligen jumps as investors revisit strong Q1 results and bioprocessing recovery outlook

Repligen Corporation (RGEN) is up 10.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a continued repricing around Repligen’s stronger first-quarter 2026 performance and management’s confidence in full-year demand, rather than a single fresh company announcement today. This could also be because investors are leaning into a broader bioprocessing recovery narrative, with Repligen viewed as a focused way to play improving spending in biologics manufacturing.

Details:

In its May 5 earnings release, Repligen posted first-quarter revenue of $194 million, up 15% year over year, with 11% organic growth.

The company also said GAAP EPS rose 50% year over year and adjusted EPS rose 23%, while full-year adjusted EPS guidance was increased to $1.97 to $2.05.

Management highlighted recent order trends, a new China OEM partnership, and a sharper focus on profitable growth after divesting a non-core filtration business.

Recent analyst actions have generally remained constructive, including maintained bullish ratings and higher price targets from some firms, which may be reinforcing momentum in the shares.

Sources:

Repligen Investor Relations, SEC, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RGEN Insider Trading Activity

$RGEN insiders have traded $RGEN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $RGEN stock by insiders over the last 6 months:

OLIVIER LOEILLOT (Chief Executive Officer) sold 3,832 shares for an estimated $536,480

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$RGEN Hedge Fund Activity

We have seen 239 institutional investors add shares of $RGEN stock to their portfolio, and 257 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MAVERICK CAPITAL LTD added 1,518,805 shares (+inf%) to their portfolio in Q1 2026, for an estimated $178,945,605
WASATCH ADVISORS LP added 1,243,531 shares (+inf%) to their portfolio in Q1 2026, for an estimated $146,512,822
VESTAL POINT CAPITAL, LP added 842,000 shares (+1014.5%) to their portfolio in Q1 2026, for an estimated $99,204,440
MILLENNIUM MANAGEMENT LLC removed 628,085 shares (-96.5%) from their portfolio in Q1 2026, for an estimated $74,000,974
BLACKROCK, INC. removed 626,217 shares (-9.5%) from their portfolio in Q1 2026, for an estimated $73,780,886
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 528,690 shares (-92.4%) from their portfolio in Q4 2025, for an estimated $86,631,143
MARSHALL WACE, LLP removed 516,336 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $60,834,707

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$RGEN Analyst Ratings

Wall Street analysts have issued reports on $RGEN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 05/06/2026

To track analyst ratings and price targets for $RGEN, check out Quiver Quantitative's $RGEN forecast page.

$RGEN Price Targets

Multiple analysts have issued price targets for $RGEN recently. We have seen 11 analysts offer price targets for $RGEN in the last 6 months, with a median target of $160.0.

Here are some recent targets:

Sidharth Sahoo from HSBC set a target price of $150.0 on 06/03/2026
Mike Polark from Wolfe Research set a target price of $145.0 on 06/02/2026
Dan Leonard from RBC Capital set a target price of $160.0 on 05/15/2026
Luke Sergott from Barclays set a target price of $160.0 on 05/06/2026
Casey Woodring from JP Morgan set a target price of $165.0 on 05/06/2026
Kyle Mikson from Canaccord Genuity set a target price of $145.0 on 04/20/2026
Natalya Davies from Roth Capital set a target price of $160.0 on 04/17/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.